CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
A phase IIb, open-label, randomized study of Nab-Paclitaxel and Gemcitabine and plus/minus VCN-01 in Patients with Metastatic Pancreatic Cancer...
Phase 2
Columbus, Ohio, United States and 16 other locations
open label, multi-center, clinical study of Chimeric Antigen Receptor T Cells (CAR-T) targeting claudin18.2 in patients with advanced gastric, pancreatic...
Phase 1, Phase 2
Columbus, Ohio, United States and 15 other locations
or without SBP-101 in subjects previously untreated for metastatic pancreatic ductal adenocarcinoma (PDA), including subjects who have recei...
Phase 2, Phase 3
Columbus, Ohio, United States and 91 other locations
agent to patients with genetically selected advanced or metastatic pancreas cancer through assessment of the overall response rate. ...
Phase 2
Columbus, Ohio, United States
The purpose of this study is to find out whether the study drug, LY4170156, is safe, tolerable and effective in participants with advanced solid tumors...
Phase 1
Columbus, Ohio, United States and 15 other locations
This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors th...
Phase 2
Columbus, Ohio, United States and 109 other locations
This is a single arm phase II study. All patients will receive 3 cycles of the treatment of nab-paclitaxel (Days 1, 8 and 15), gemcitabine (Days 1, 8...
Phase 2
Columbus, Ohio, United States
This is a Phase 2, multicenter, open-label, 3-arm, randomized, parallel group study to evaluate the efficacy and safety of TTX-030 with or without bu...
Phase 2
Columbus, Ohio, United States and 63 other locations
anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in participants with advanced or metastatic solid tumors...
Phase 1, Phase 2
Columbus, Ohio, United States and 36 other locations
This is an open-label, multi-center, phase 1b study designed to determine a tolerable dose of CX-5461 administered by IV infusion on Day 1 and Day 8...
Phase 1
Columbus, Ohio, United States and 7 other locations
Clinical trials
Research sites
Resources
Legal